Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19167949 | 0.80 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL14458040 | 0.80 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL11992929 | 0.75 | — | — | |
| SCHEMBL11310612 | 0.75 | — | — | |
| SCHEMBL28286306 | 0.74 | — | — | |
| SCHEMBL11157230 | 0.72 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL22108016 | 0.69 | ALDH1A1 (0.30) | CYP3A4 | |
| SCHEMBL22141049 | 0.69 | MET (0.31) | — | |
| SCHEMBL14598875 | 0.69 | ALDH1A1 (0.30) | CYP3A4 | |
| SCHEMBL13705527 | 0.68 | ALDH1A1 (0.35) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | DHCR7, HSD17B7, HSD11B1 | CYP3A4 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.